{
    "clinical_study": {
        "@rank": "70433", 
        "acronym": "APPROVE", 
        "arm_group": [
            {
                "arm_group_label": "Azelnidipine&Perindopril", 
                "arm_group_type": "Active Comparator", 
                "description": "Azelnidipine 8mg~16mg(with or without hydrochlorothiazide) or Perindopril 2mg~4mg(with or without hydrochlorothiazide) by mouth per day for 2 years."
            }, 
            {
                "arm_group_label": "Blood pressure controlling", 
                "arm_group_type": "Active Comparator", 
                "description": "Blood pressure controlled between 120 mmHg~130 mmHg or below 120 mmHg."
            }
        ], 
        "brief_summary": {
            "textblock": "A. the controlling of the blood pressure, especially the variation of blood pressure, can\n      slow down the development of the small vessel disease.\n\n      B intensive BP control is more effective than normal control of blood pressure in slowing\n      down the small vessel disease.\n\n      C drugs of Calcium Channel Blocker(CCB) and Angiotensin-Converting Enzyme Inhibitor(ACEI)\n      have no significant difference in lowing the blood pressure and variability of blood\n      pressure"
        }, 
        "brief_title": "Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cerebral Small Vessel Diseases", 
        "detailed_description": {
            "textblock": "The selected patients were diagnosis of stroke caused by small vessel disease due to\n      hypertension recently.\n\n      The patients had been divided into two groups by random principle and given ACEI or CCB\n      separately for treatment. At the same time, given intensive or regular controlling of the\n      blood pressure by stratified random. In the regular controlling group, the BP should be in\n      the range of 130-139 mmHg and in the intensive controlling group, the BP should be below 130\n      mmHg. To the acute ischemic stroke patients who were accord with the lacunar infarction\n      syndrome, it is rule to do the examination for exclusive selection of exclusion of\n      hemodynamic dysfunction due to the artery stenosis ( stenosis >50%, the examination of\n      intracranial artery was by the methods of Transcranial Doppler (TCD)/Magnetic Resonance\n      Angiography(MRA)/Computed Tomographic Angiography(CTA)/Digital Subtraction Angiography(DSA),\n      the examination of carotid artery was by the methods of colorful ultrasound / MRA/ CTA/ DSA\n      ) at the baseline.\n\n      It should be proved of lacunar infarction by brain imaging. All patients had a MRI scan at\n      the baseline and the beginning of the research, including T1-Weighted\n      Imaging(T1W1),T2-Weighted Imaging(T2WI), T2-FLAIR, Diffusion-Weighted Imaging(DWI),\n      Gradient-Recalled Echo(GRE) T2*, the Perfusion-Weighted Imaging(PWI) would complete\n      conditionally (100 cases). The details should be followed by the instruction in the\n      appendix.\n\n      Research about the variability of blood pressure: all patients show complete the examination\n      of 24-hour blood-pressure monitor (at the baseline, the first month after the beginning,\n      every three months and the end of the research), complete the head-up tilt test if\n      conditionally ( at the baseline, each 3 months later and the end of the research ) The\n      automatic regulation function of the small vessel should be evaluated if conditionally (the\n      C02 reaction, TCD head-up tilt) and also the function of endothelium-derived relaxing of the\n      brachial artery (at the baseline, each 3 months later and the end of the research) The\n      reservation of the blood was for further research on genetic study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cerebral infarction within 10 days to 6 months.\n\n          -  Clinical manifestation represented as lacunar infarction syndrome; without aphasia or\n             disturbance of consciousness.\n\n          -  Mini-Mental State Examination(MMSE)>24 and modified Rankin Score(mRS)\u22643.\n\n          -  History of hypertension, and need to be treated with drugs; patient who had been\n             diagnosis hypertension or the first time with the diagnosis of this disease after the\n             guideline of China 2010 (measurement of the BP in the seated posture of the up arm\n             after having a rest for 5 minutes and was taken for three times and calculated the\n             average result, make sure the difference of BP between right and left arm are not\n             beyond the criteria of 20 mmHg and the right arm for consistence. The patients have\n             different BP between both sides which the difference beyond 20 mmHg need to exam for\n             the stenosis of subclavian artery.\n\n          -  MRI confirm the lesion for lacunar infarction and be responsible for the clinical\n             symptom located in the region of perforating artery and the diameter of the lesion is\n             less than 20mm.\n\n          -  The examinations of carotid artery and intracranial artery have excluded hemodynamic\n             abnormalities due to artery stenosis ( stenosis >50%, the examination of intracranial\n             artery was by the methods of TCD/ MRA/ CTA/ DSA, the examination of carotid artery\n             was by the methods of colorful ultrasound / MRA/ CTA/ DSA ). The combination of\n             thickness Intima media or plaque of the carotid artery without the hemodynamic\n             dysfunction can be enrolled in this research.\n\n          -  Informed consent was signed.\n\n        Exclusion Criteria:\n\n          -  Hypertension diffcult to control, instantly over 220/ 120 mmHg.\n\n          -  History of atrial fibrillation (Paroxysmal or sustained).\n\n          -  History of heart infarction within 6 months.\n\n          -  Stenosis above 50% or hemodynamic dysfunction in carotid and intracranial artery\n             after examination.\n\n          -  Unknown caused of brain infarction, like dissection vascular, Moyamoya disease,\n             vasculitis, hereditary small angiopathy ( eg,Cerebral Autosomal Dominant Arteriopathy\n             with Subcortical Infarcts and Leucoencephalopathy(CADASIL), FABRY, mitochondrial\n             encephalopathy).\n\n          -  Severe liver and renal disease. the definition of sever liver disease was Alanine\n             aminotransferase(ALT) or Aspartate aminotransferase(AST) 4 times than the normal\n             level, or the total bilirubin above 20 mmol/L, or cirrhosis. the definition of sever\n             renal disease was stenosis of renal artery and dysfunction of renal (clearance rate\n             of creatinine <60ml/min or serum creatinine >265mmol/L).\n\n          -  History of hemorrhage.\n\n          -  Active bleeding disease or clear coagulation disorders.\n\n          -  Malignant neoplasm.\n\n          -  Pregnancy.\n\n          -  Severe organic diseases, expected lifetime was shorter than 2 years.\n\n          -  Conditions contraindicated for CCB or ACEI, such as hyperpotassaemia (serum potassium\n             >5.5mmol/L) or have the evidence proved allergic to both drugs.\n\n          -  Eenrolled in another clinical trial in 30 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "1200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819441", 
            "org_study_id": "Peking University", 
            "secondary_id": "APPROVE"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Azelnidipine&Perindopril", 
                    "Blood pressure controlling"
                ], 
                "intervention_name": "Azelnidipine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Azelnidipine&Perindopril", 
                    "Blood pressure controlling"
                ], 
                "intervention_name": "Perindopril", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Perindopril"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "cerebral small Vessel diseases,  blood pressure,CCB, ACEI", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "contact": {
                "email": "npku@yahoo.com.cn", 
                "last_name": "Yining Huang"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100034"
                }, 
                "name": "Peking University First Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Azelnidipine vs Perindopril and Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients (APPROVE):Multi-center Randomized Controlled Clinical Trial", 
        "overall_contact": {
            "last_name": "Peking University First Hospital"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "China: Ministry of Science and Technology"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "white matter lesion", 
            "safety_issue": "No", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819441"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University First Hospital", 
            "investigator_full_name": "Yining Huang", 
            "investigator_title": "chairman", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Peking University First Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yining Huang", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}